Evidence map›Paper›PMID 34882581›Full record

Trial reportThe Journal of clinical investigation2022

Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.

Hirokazu Ogino, Jennie W Taylor, Takahide Nejo, David Gibson, Payal B Watchmaker, Kaori Okada, Atsuro Saijo, Meghan R Tedesco, Anny Shai, Cynthia M Wong and 15 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02549833 (Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines in Adult Patients With WHO Grade II Glioma), which is not on this map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02549833 phase1completednot on this map

Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines in Adult Patients With WHO Grade II Glioma

TypeinterventionalSponsorJennie TaylorRan2016 to 2024Enrolled28ConditionsOligodendroglioma, Astrocytoma, Grade II, Glioma, Astrocytic, GliomaArmsGBM6-AD and poly-ICLC before and after surgery, GBM6-AD and poly-ICLC after surgery only
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Immunotherapy in central nervous system tumors.International journal of surgery (London, England) · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 2 countries.

Hirokazu OginoDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Jennie W TaylorDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Takahide NejoDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
David GibsonDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Payal B WatchmakerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Kaori OkadaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Atsuro SaijoDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Meghan R TedescoDepartment of Neurology.
Anny ShaiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Cynthia M WongDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Jane E RabbittDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Michael R OlinDivision of Pediatric Hematology/Oncology, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
Christopher L MoertelDivision of Pediatric Hematology/Oncology, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
Yasuhiko NishiokaDepartment of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Andres M SalazarOncovir Inc., Washington, DC, USA.
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Joanna J PhillipsDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Nicholas A ButowskiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Jennifer L ClarkeDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Nancy Ann Oberheim BushDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Shawn L Hervey-JumperDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Philip TheodosopoulosDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Susan M ChangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Mitchel S BergerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Hideho OkadaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · USUniversity of Minnesota · USOncovir (United States) · USTokushima University · JP

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
Preclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0M
Pilot randomized neoadjuvant vaccine with CD27-costimulation in low-grade gliomaR21CA233856 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2019 to 2020
$318k
NCI NIH HHS P50 CA097257NCI NIH HHS R21 CA233856NINDS NIH HHS R35 NS105068
6 · The paper itself

Abstract

BACKGROUNDLong-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment strategy.METHODSWe conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGGs. Patients were randomized to receive the vaccines before surgery (arm 1) or not (arm 2) and all patients received adjuvant vaccines. Coprimary outcomes were to evaluate safety and immune response in the tumor.RESULTSA total of 17 eligible patients were enrolled - 9 in arm 1 and 8 in arm 2. This regimen was well tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines and increased activated CD8+ T cells in peripheral blood. Single-cell RNA/T cell receptor sequencing detected CD8+ T cell clones that expanded with effector phenotype and migrated into the tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident-like CD8+ T cells with effector memory phenotype in the TME after the neoadjuvant vaccination.CONCLUSIONThe regimen induced effector CD8+ T cell response in peripheral blood and enabled vaccine-reactive CD8+ T cells to migrate into the TME. Further refinements of the regimen may have to be integrated into future strategies.TRIAL REGISTRATIONClinicalTrials.gov NCT02549833.FUNDINGNIH (1R35NS105068, 1R21CA233856), Dabbiere Foundation, Parker Institute for Cancer Immunotherapy, and Daiichi Sankyo Foundation of Life Science.

Indexed as

Cancer VaccinesGliomaNeoadjuvant TherapyVaccinationAdultAgedCarboxymethylcellulose SodiumCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedPoly I-CPolylysineTumor MicroenvironmentCancer VaccinesCarboxymethylcellulose SodiumPoly I-Cpoly ICLCPolylysineBrain cancerCancer immunotherapyOncologyT cellsVaccines

Identifiers

PMID34882581
PMCPMC8803342
OpenAlexW4200400638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.